Compare OPXS & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPXS | PMVP |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Electronic Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6M | 76.8M |
| IPO Year | 2009 | 2020 |
| Metric | OPXS | PMVP |
|---|---|---|
| Price | $12.17 | $1.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.10 | N/A |
| AVG Volume (30 Days) | 42.9K | ★ 408.7K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.55 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $24,530,000.00 | N/A |
| Revenue This Year | $39.17 | N/A |
| Revenue Next Year | $0.53 | N/A |
| P/E Ratio | $52.13 | ★ N/A |
| Revenue Growth | ★ 17.63 | N/A |
| 52 Week Low | $8.42 | $0.96 |
| 52 Week High | $17.76 | $1.88 |
| Indicator | OPXS | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 59.91 | 33.71 |
| Support Level | $10.05 | $1.12 |
| Resistance Level | $13.07 | $1.26 |
| Average True Range (ATR) | 0.71 | 0.06 |
| MACD | 0.17 | -0.01 |
| Stochastic Oscillator | 81.49 | 4.35 |
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson, Applied Optics Center Dallas, and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor, and others.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.